Interestingly, glioma patients with PHF20 autoantibody have significantly better prognosis than patients without this autoantibody, indicating that a potential therapeutic option for the treatment of GBM is to develop immunotherapy or targeting therapy against PHF20. Here, PHF20 is linked to glioma.